Novo Nordisk has officially begun building a $1.8 billion production facility for diabetes medicines at its Clayton site that will create 700 ... 5,000 employees in the United States. Accelerate NC ...

What qualities are you looking for in a great employer? Use our tool to find the companies on our list that suit you best.

At Amgen North Carolina, we see the apprenticeship program we developed in partnership with Wake Tech Community College, as a ...

Novo Nordisk has reduced its sales and profits forecasts for 2025 due to lower-than-expected demand in the US for blockbuster weight loss and diabetes drugs, though shares in the company were ...

Novo Nordisk now forecasts 2025 sales growth between 13% and 21%, and operating profit growth between 16% and 24% at constant exchange rates (CER), down 3 and 5 percentage points respectively from ...

LONDON/COPENHAGEN, May 7 (Reuters) - Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President Donald Trump's executive order to reduce the time it takes to ...

Novo Nordisk (NYSE: NVO), the Danish drugmaker that's been riding high ever since it began putting out Ozempic and Wegovy GLP-1 injectables for treatment of diabetes and weight loss, got another ...

Novo Nordisk said first-quarter sales of Wegovy were 17.36 billion Danish crowns ($2.64 billion), declining 13% from the previous quarter, and below the 18.7 billion crowns expected by analysts.

Novo Nordisk has submitted an "Ozempic pill" to the FDA for approval. The new pill will probably be popular (if approved). However, making it will require Novo Nordisk to ramp up semaglutide ...

Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But that’s reflective of the tough times the Danish maker of Ozempic and ...

Good day, and thank you for standing by. Welcome to the Q1 2025 Novo Nordisk A/S Earnings Conference Call. [Operator Instructions]. Please be advised that today's conference is being recorded.